HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

COVA1-18

a SARS-CoV-2 neutralizing monoclonal antibody isolated from COVID-19 patient

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Aldon, Yoann: 1 article (10/2021)
2.	Bijl, Tom P L: 1 article (10/2021)
3.	Bontjer, Ilja: 1 article (10/2021)
4.	Brinkkemper, Mitch: 1 article (10/2021)
5.	Brouwer, Philip J M: 1 article (10/2021)
6.	Bukreyev, Alexander: 1 article (10/2021)
7.	Burger, Judith A: 1 article (10/2021)
8.	Caniels, Tom G: 1 article (10/2021)
9.	Chapon, Catherine: 1 article (10/2021)
10.	Chesnais, Virginie: 1 article (10/2021)

Related Diseases

1.

Lymphopenia (Lymphocytopenia)

10/20/2021 - "Using a mathematical model, we estimate that COVA1-18 reduces viral infectivity by more than 95% in these compartments, preventing lymphopenia and extensive lung lesions. "
02/15/2021 - "When administered at 10 mg kg - 1 one day prior to a high dose SARS-CoV-2 challenge in cynomolgus macaques, COVA1-18 had a very strong antiviral activity in the upper respiratory compartments with an estimated reduction in viral infectivity of more than 95%, and prevented lymphopenia and extensive lung lesions. "

Related Drugs and Biologics

1.	Dihydrotachysterol (AT 10)
2.	Antiviral Agents (Antivirals)